Aktis Oncology's AKY-2519 Radioconjugate Shows Robust Tumor Uptake, Limited Normal Tissue Exposure in Early Data
AKTS sits 30% above its 52-week low of $14.72.
Summary
Aktis Oncology announced positive first-in-human clinical imaging and dosimetry data for its AKY-2519 radioconjugate. The data demonstrated robust tumor uptake and limited normal tissue exposure in patients with B7-H3 expressing tumors. This follows the FDA clearance of AKY-2519's IND application in March and the initiation of its Phase 1b clinical trial in early May. These early results are a strong positive signal, suggesting a favorable safety and biodistribution profile crucial for an oncology therapeutic, and support the drug's broad clinical development. Preliminary data from the ongoing mCRPC trial is anticipated in 2027.
At the time of this announcement, AKTS was trading at $19.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $14.72 to $24.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.